Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other 1Gynecologic 1

Conditions

Obesity 1Neoplasm Metastasis 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Disease 1Carcinosarcoma 1

Interventions

Specimen Handling 9Paclitaxel 7Magnetic Resonance Spectroscopy 6Carboplatin 6Biopsy 6Nivolumab 5pembrolizumab 3olaparib 3X-Rays 3durvalumab 2ceralasertib 2cediranib 2Taxes 2Immunoglobulin G 2trastuzumab deruxtecan 1sargramostim 1rucaparib 1ribociclib 1rebastinib 1pelcitoclax 1pazopanib 1pamiparib 1liposomal doxorubicin 1cobimetinib 1capivasertib 1cabozantinib 1belinostat 1atezolizumab 1apatinib 1Trabectedin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinosarcoma × TIC10 compound × Sarcoma × Clear all
NCT05542407 2026-01-29

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
58 enrolled
GynecologicOtherSarcoma

Carcinosarcoma, Disease, Neoplasm Metastasis, Obesity, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡